Explanipedia

Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care Open

Maria Antonietta Cerone, Tara C. Mills, Rowena Sharpe, David J. McBride, Moira MacDonald , et al. · 2023

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care Open

Maria Antonietta Cerone, Tara C. Mills, Rowena Sharpe, David J. McBride, Moira MacDonald , et al. · 2023

Clinical Analysis of the Colorectal Cohort within the Wales Cancer Biobank: A Study of Outcomes and Genetic Screening Open

Lisa K. Spary, Katie De‐loyde, Helen Roberts, Fiona Martin, Chi Pooi Lee , et al. · 2023

Over the last 12 years, the Wales Cancer Biobank (WCB) has consented to more than 2000 patients with colorectal cancer (CRC). From these patients, clinical data has been collected and patients have been followed through their cancer journe…

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT Open

Louise Brown, David J. Fisher, Richard Adams, Jenny F. Seligmann, Michel Seymour , et al. · 2022

Background Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame. There is evidence that patients with colorectal cancer fall into different subg…

Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement Open

Neal Navani, Rachel Butler, Salma Ibrahimo, Anjali Verma, Matthew Evans , et al. · 2022

Targeted therapy against actionable variants has revolutionised the treatment landscape for non-small cell lung cancer (NSCLC). Approximately half of NSCLC adenocarcinomas have an actionable variant, making molecular testing a critical com…

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial Open

Sacha J. Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler , et al. · 2022

AstraZeneca and Cancer Research UK.

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing Open

Susan D. Richman, Gemma Hemmings, Helen Roberts, Niall Gallop, Rachel Dodds , et al. · 2022

Aims FOCUS4 was a phase II/III umbrella trial, recruiting patients with advanced or metastatic colorectal cancer, between 2014 and 2020. Molecular profiling of patients’ formalin-fixed, paraffin-embedded tumour blocks was undertaken at two…

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer Open

Louise Brown, Janet Graham, David J. Fisher, Richard Adams, Jenny F. Seligmann , et al. · 2022

Background: Complex innovative design trials are becoming increasingly common and offer potential for improving patient outcomes in a faster time frame. FOCUS4 was the first molecularly stratified trial in metastatic colorectal cancer and …

APOE gene testing in FH referrals – the story so far Open

Celia Duff‐Farrier, M. Pennock, E. Watson, Natalie Forrester, Sarah Marsh , et al. · 2021

Genomic testing in patients with suspected Familial Chylomicronaemia Syndrome (FCS) and evaluation of the FCS clinical scoring tool Open

J. C. Evans, Paul Downie, Graham Bayly, Handrean Soran, Emily M. Price , et al. · 2021

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling Open

Ainhoa Arana Echarri, Mark Beresford, John P. Campbell, Robert H. Jones, Rachel Butler , et al. · 2021

Breast cancer is the most common malignancy among women worldwide. Over the last four decades, diagnostic and therapeutic procedures have improved substantially, giving patients with localized disease a better chance of cure, and those wit…

Correction to: A pilot study of improved psychological distress with art therapy in patients with cancer undergoing chemotherapy Open

Elizabeth Blessing Elimimian, Leah Elson, Elizabeth Stone, Rachel Butler, Madeleine Doll , et al. · 2020

A pilot study of improved psychological distress with art therapy in patients with cancer undergoing chemotherapy Open

Elizabeth Blessing Elimimian, Leah Elson, Elizabeth Stone, Rachel Butler, Madeleine Doll , et al. · 2020

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial Open

Robert H. Jones, Angela Casbard, Margherita Carucci, Catrin Cox, Rachel Butler , et al. · 2020

IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing Open

Zandra C. Deans, Rachel Butler, Melanie H. Cheetham, Elisabeth Dequeker, Jennifer A. Fairley , et al. · 2019

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA Open

Cleo Keppens, Elisabeth Dequeker, Simon Patton, Nicola Normanno, Francesca Fenizia , et al. · 2018

HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee Open

Newton A C S Wong, Fernanda Amary, Rachel Butler, Richard Byers, David González , et al. · 2018

The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat wi…

Additional file 2: of International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA Open

Cleo Keppens, Elisabeth Dequeker, Simon Patton, Nicola Normanno, Francesca Fenizia , et al. · 2018

Table S2. Description: Detailed overview of the mutation detection techniques used by the EQA participants. (XLSX 12 kb)

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme Open

Colin R. Lindsay, Emily Shaw, Fiona Blackhall, Kevin G. Blyth, James D. Brenton , et al. · 2018

Nationwide molecular pathology testing in a non-trial setting is feasible. The experience with SMP1 has been used to inform ongoing CRUK flagship programmes such as the CRUK National Lung MATRIX trial and TRACERx.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial Open

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk , et al. · 2017

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey Open

Zandra C. Deans, Hannah L. Williams, Elisabeth Dequeker, Cleo Keppens, Nicola Normanno , et al. · 2017

RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016) Open

Susan D. Richman, Jennifer A. Fairley, Rachel Butler, Zandra C. Deans · 2017

Evidence strongly indicates that extended RAS testing should be undertaken in mCRC patients, prior to prescribing anti-EGFR therapies. With more laboratories implementing testing, the requirement for External Quality Assurance schemes incr…

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma Open

Rhian Siân Davies, Christian Smith, Gwenllian Edwards, Rachel Butler, Diane Parry , et al. · 2017

Objectives . There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epid…

Index Open

Edward Grigg, Amery Julian, Amery Leo, Eleanor Bron, John Buchán , et al. · 2017

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS Open

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, S. Falk , et al. · 2016

How close are we to standardised extended <i>RAS</i> gene mutation testing? The UK NEQAS evaluation Open

Susan D. Richman, Jennifer A. Fairley, Rachel Butler, Zandra C. Deans · 2016

Aims Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS ’ analyses have…

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial Open

Susan D. Richman, Richard Adams, Philip Quirke, Rachel Butler, Gemma Hemmings , et al. · 2015

Introduction Molecular characterisation of tumours is increasing personalisation of cancer therapy, tailored to an individual and their cancer. FOCUS4 is a molecularly stratified clinical trial for patients with advanced colorectal cancer.…

Rachel Butler YOU? Author Swipe